Role of dopaminergic treatment in dopamine receptor down-regulation in advanced parkinson disease: A positron emission tomographic study

Archives of Neurology

Volumn 61, Issue 11, 2004, Pages 1705-1709

  Thobois, Stéphane ^a,b   Vingerhoets, François ^c   Fraix, Valerie ^d   Xie Brustolin, Jing ^a   Mollion, Hélène ^a   Costes, Nicolas ^a   Mertens, Patrick ^a   Benabid, Alim Louis ^d   Pollak, Pierre ^d   Broussolle, Emmanuel ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; RACLOPRIDE;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG INTERMITTENT THERAPY; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SUBTHALAMIC NUCLEUS;

AGED; DISEASE PROGRESSION; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DOWN-REGULATION; ELECTRIC STIMULATION THERAPY; FEMALE; HUMANS; LIGANDS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SUBTHALAMIC NUCLEUS;

EID: 7744235165     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.11.1705     Document Type: Article

References (26)

1. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 receptor binding in the living human brain by PET. Science. 1986;231:258-261.
2. Rinne UK, Laihinen A, Rinne JO, Nagren K, Bergman J, Ruotsalainen U. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord. 1990;5:55-59.
3. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol. 1992;31:184-192.
4. Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RS. Asymmetrical presynaptic and post-synaptic changes in the striatal dopamine projection in dopa naive parkinsonism: diagnostic implications of the D2 receptor status. Brain. 1993;116:853-867.
5. Rinne JO, Laihinen A, Ruottinen H, et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride. J Neurol Sci. 1995;132:156-161.
6. Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. [11C]Raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology. 1994;44:1325-1329.
7. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord. 1997;12:33-38.
8. Dentresangle C, Veyre L, Le Bars D, et al. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study. Mov Disord. 1999;14:1025-1030.
9. Kaasinen V, Ruottinen HM, Nagren K, Lehikoinen P, Oikonen V, Rinne JO. Up-regulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med. 2000;41:65-70.
10. Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology. 1996;46:1430-1436.
11. Linazasoro G, Obeso JA, Gomez JC, Martinez M, Antonini A, Leenders KL. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET. Clin Neuropharmacol. 1999;22:277-280.
12. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 1998;339:1105-1111.
13. Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol. 1989;15:27-44.
14. Fahn S, Elton RL; UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Development in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
15. 11C]-raclopride PET study. J Neurol. 2003;250:1219-1223.
16. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1 and D2 dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology. 1994;11:245-256.
17. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;(4, pt 1):153-158.
18. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RJS. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1995;2:189-210.
19. Talairach J, Tournoux P. Coplanar Stereotaxic Atlas of the Human Brain. New York, NY: Thieme Verlag; 1988.
20. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature. 1978;273:59-61.
21. Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol. 1984;99:167-175.
22. Hall MD, Cooper DR, Fleminger S, Rupniak NM, Jenner P, Marsden CD. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats. Neuropharmacology. 1984;23:545-553.
23. Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW. Dopamine D2 receptor density remains constant in treated Parkinson's disease. Ann Neurol. 1986;19:487-492.
24. Barbier P, Colelli A, Maggio R, Bravi D, Corsini GU. Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration. J Neural Transm. 1997;104:867-874.
25. Creese I, Burt DR, Snyder SH. Dopamine receptor binding enhancement accompanies lesion-induced behavioral sensitivity. Science. 1977;197:596-598.
26. Joyce JN, Marshall JF, Bankiewicz KS, Kopin IJ, Jacobowitz DM. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res. 1986;382:360-364.